iRhythm Holdings, Inc. (IRTC)
| Market Cap | 3.84B +15.3% |
| Revenue (ttm) | 787.85M +27.4% |
| Net Income | -27.78M |
| EPS | -0.86 |
| Shares Out | 32.86M |
| PE Ratio | n/a |
| Forward PE | 419.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 485,382 |
| Open | 120.53 |
| Previous Close | 120.66 |
| Day's Range | 115.56 - 122.79 |
| 52-Week Range | 112.31 - 212.00 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 187.62 (+60.58%) |
| Earnings Date | Apr 30, 2026 |
About IRTC
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRTC stock is "Strong Buy." The 12-month stock price target is $187.62, which is an increase of 60.58% from the latest price.
News
iRhythm price target raised to $157 from $155 at Citi
Citi raised the firm’s price target on iRhythm (IRTC) to $157 from $155 and keeps a Buy rating on the shares.
iRhythm price target raised to $174 from $170 at Truist
Truist raised the firm’s price target on iRhythm (IRTC) to $174 from $170 and keeps a Buy rating on the shares. The company delivered another strong revenue and EBITDA beat…
iRhythm price target raised to $175 from $166 at Baird
Baird raised the firm’s price target on iRhythm (IRTC) to $175 from $166 and keeps an Outperform rating on the shares. The firm updated its model following beat and raise…
iRhythm price target lowered to $175 from $215 at JPMorgan
JPMorgan lowered the firm’s price target on iRhythm (IRTC) to $175 from $215 and keeps an Overweight rating on the shares.
iRhythm price target lowered to $185 from $225 at Oppenheimer
Oppenheimer lowered the firm’s price target on iRhythm (IRTC) to $185 from $225 and keeps an Outperform rating on the shares following quarterly results. The firm notes there were no…
iRhythm price target lowered to $160 from $170 at Evercore ISI
Evercore ISI lowered the firm’s price target on iRhythm (IRTC) to $160 from $170 and keeps an Outperform rating on the shares.
iRhythm price target raised to $255 from $254 at Needham
Needham raised the firm’s price target on iRhythm (IRTC) to $255 from $254 and keeps a Buy rating on the shares after its Q1 earnings beat. The company continues to…
iRhythm price target lowered to $180 from $198 at Canaccord
Canaccord lowered the firm’s price target on iRhythm (IRTC) to $180 from $198 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1 with…
iRhythm Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 25.7% revenue growth, margin expansion, and improved profitability, driven by strong volume across core and emerging channels. Guidance for 2026 was raised, with continued investment in AI, workflow integration, and international growth.
iRhythm sees FY26 revenue $875M-$885M, consensus $876.16M
For the full year 2026, iRhythm (IRTC) expects revenue between $875 million and $885 million and adjusted EBITDA margin between 12% and 13%, reflecting continued volume-led growth, gross margin expans...
iRhythm Holdings Announces First Quarter 2026 Financial Results
SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent d...
iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict di...
New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio ® ...
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict di...
iRhythm price target lowered to $170 from $200 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $170 from $200 and keeps a Buy rating on the shares as part of a broader research…
iRhythm price target lowered to $185 from $215 at BTIG
BTIG lowered the firm’s price target on iRhythm (IRTC) to $185 from $215 and keeps a Buy rating on the shares as part of a broader research name on Medical…
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
iRhythm price target lowered to $155 from $214 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on iRhythm (IRTC) to $155 from $214 and keeps a Buy rating on the shares. The firm adjusted targets in the…
iRhythm price target lowered to $170 from $210 at Evercore ISI
Evercore ISI lowered the firm’s price target on iRhythm (IRTC) to $170 from $210 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio ® ambulatory ECG portfolio. 1,2 Chief Medical Officer Mintu Tur...
iRhythm Holdings Appoints Jason Patten to its Board of Directors
SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent d...
iRhythm price target lowered to $214 from $242 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on iRhythm (IRTC) to $214 from $242 and keeps a Buy rating on the shares. The firm adjusted targets in the…
iRhythm price target lowered to $200 from $215 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $200 from $215 but keeps a Buy rating on the shares. The company delivered Q4 revenue as…
iRhythm price target lowered to $184 from $211 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on iRhythm (IRTC) to $184 from $211 and keeps a Neutral rating on the shares.
iRhythm should be bought on subpoena weakness, says William Blair
William Blair analyst Brandon Vazquez says shares of iRhythm (IRTC) are trading off 6% after the company disclosed it received a civil investigative demand from the Department of Justice in…